| Literature DB >> 27066435 |
O Young Kwon1, Gun Jik Kim1, Woo Sung Jang1, Young Ok Lee1, Jun Yong Cho1, Jong Tae Lee1.
Abstract
Although cardiac myxoma is the most commonly encountered benign cardiac tumor in cardiac surgery practice, recurrent cardiac myxoma is very rare, is most commonly related to the Carney complex, and usually requires multiple cardiac operations with specific requirements in terms of perioperative management. In this report, we describe a patient who experienced the fourth recurrence of cardiac myxoma and review the diagnostic criteria of the Carney complex. This is the first report of such a case in Korea.Entities:
Keywords: Heart neoplasms; Myxoma
Year: 2016 PMID: 27066435 PMCID: PMC4825914 DOI: 10.5090/kjtcs.2016.49.2.119
Source DB: PubMed Journal: Korean J Thorac Cardiovasc Surg ISSN: 2233-601X
Fig. 1(A) Chest computed tomography and echocardiography revealed a 7.3-cm recurrent right atrial tumor (white arrow). (B) Two-dimensional echocardiography confirmed the presence of an intra-cardiac mass in the right atrium, extending to the right ventricle.
Fig. 2The gelatinous cardiac tumor occupied the entire right atrial and ventricular cavities and was firmly attached to the right atrium-inferior vena cava junction.
Diagnostic criteria for carney complex
| Content | |
|---|---|
| Main criteria |
Spotty skin pigmentation with a typical distribution (lips, conjunctiva and inner or outer canthi, vaginal and penile mucosa) Myxoma (cutaneous and mucosal) Cardiac myxoma Breast myxomatosis Primary pigmented nodular adrenocortical disease Acromegaly due to GH-producing adenoma Large-cell calcifying Sertoli cell tumor Thyroid carcinoma Psammomatous melanotic schwannoma Blue nevus, epithelioid blue nevus (multiple) Breast ductal adenoma (multiple) Osteochondromyxoma |
| Supplemental criteria |
Affected first-degree relative Inactivating mutation of the |
To make a diagnosis of Carney complex, a patient must exhibit either: (1) two of the manifestations of the disease listed or (2) one of these manifestations and meet one of the supplemental criteria (an affected first-degree relative or an inactivating mutation of the PRKAR1A gene). From Stratakis, et al. J Clin Endocrinol Metab 2001;86:4041–6 [6].
With histologic confirmation.